Abigail Brooks, MA

The living guideline incorporates new medications and the latest data to make recommendations for moderate-to-severely active CD care.

The analysis of data from a single-source rare disease specialty pharmacy sheds light on high treatment adherence and low discontinuation of Cuvrior.

Findings showed elafibranor led to expression changes of proteins linked to fatigue or mitochondrial function, significantly correlated with each other and with fatigue improvement.

Findings suggest AOOS in liver transplantation is widespread across the US and benefits a small subset of centers, undermining equity and transparency in allocation.

A post hoc analysis of the phase 2b SYMMETRY trial highlights efruxifermin’s impact on overall fibrosis burden and septa area.

The new guidance seeks to aid patient selection, comorbidity management, and monitoring the safety and effectiveness of semaglutide for MASH.

Findings support a sex-specific approach to MetALD and ALD definitions and the need to incorporate binge drinking frequency into clinical risk stratification.

The decision makes linaclotide (Linzess) capsules the first FDA-approved treatment for pediatric patients 7 years and older with irritable bowel syndrome with constipation.

View slated expert interviews and 5 clinical trials to watch at AASLD The Liver Meeting 2025.

Check out the latest GI FDA news, new trial data in IBD, headlines from ACG 2025, and more.

Check out the latest episode of Liver Lineup on alcohol-associated liver disease, new data on resmetirom, hepatic headlines from ACG 2025, and more.

Markov model findings showed elafibranor provided greater health benefit at a lower cost than seladelpar in ursodeoxycholic acid incomplete responders.

GLP-1 RA use was linked to a significant survival benefit and reduced risk of iron deficiency anemia in patients with celiac disease.

Real-world data suggest adding fibrates to first-line UDCA incurs several clinical benefits, including reductions in spontaneous bacterial peritonitis and hospitalizations.

Despite bearing a greater obesity burden, Black, Hispanic, and American Indian/Native individuals are underrepresented in GLP-1 RA RCTs for weight loss.

Findings from a prespecified analysis of the phase 3 MAESTRO-NASH trial highlight resmetirom’s consistent benefit with background SGLT2i or GLP-1 RA treatment.

Findings suggest having GERD incurs an 18% greater risk of a new AUD diagnosis, presenting an opportunity to discuss alcohol use with patients.

View slated expert interviews and 6 clinical GI, hepatology, and endoscopy trials to watch at ACG 2025.

The ACP Performance Measurement Committee reviewed 5 performance measures for CRC screening, ultimately only supporting 1 of them.

Findings from the quality improvement study provide real-world data supporting empirical donor exclusion and multiple-dose capsule FMT to increase CDI cure rates.

The FDA approved expanded indications for adalimumab-aaty (Yuflyma) and its unbranded version to include the treatment of adolescent HS and pediatric UV.

Final results from APPLAUSE-IgAN demonstrate iptacopan’s superiority versus placebo for slowing IgAN progression and will be used to support its full approval.

The phase 3 data reinforce iptacopan’s safety and efficacy in C3G and support its recent US Food and Drug Administration approval for this indication.

The decision updates the indication statements for ulcerative colitis and Crohn’s disease to allow use in patients who have received ≥ 1 approved systemic therapy.

The sBLA for insulin human Inhalation Powder in children and adolescents with type 1 or type 2 diabetes was assigned a PDUFA target action date of May 29, 2026.

Increases in short-term kidney function decline were observed following post-COVID-19 vaccination gross hematuria in individuals with IgA nephropathy.

LUCENT-3 open-label extension study data establish mirikizumab-mrkz (Omvoh) as the first and only IL-23p19 to show sustained long-term outcomes in UC through 4 years.

High intake of both sugar-sweetened beverages and low- or non-sugar-sweetened beverages was linked to greater MASLD risk.

The Q3 recap for gastroenterology spotlights key FDA decisions, new AGA gastroparesis guidelines, and other top GI news and research.

The approval is supported by data from the INTEGUMENT-PED phase 3 trial, the INTEGUMENT-OLE long-term extension study, and a phase 1 pharmacokinetic study.